X

Comments

X

Transcript

About this Series

CAR T-cell therapy has shown dramatic results in several blood cancers and was recently named the scientific breakthrough of 2018 by the American Society of Clinical Oncology. Now that CAR T-cell therapy is FDA approved for patients with relapsing non-Hodgkin lymphoma, oncologists and patients alike are raising questions regarding who is an appropriate candidate, what levels of patient preparation and medical infrastructure are required, and how are the unique side effects of this therapy best managed? The vanguard team at the Moffitt Cancer Center in Tampa, Florida, and patients who have undergone CAR T-cell infusion discuss key strategies in successfully navigating this breakthrough therapy.

Show More

Who's Who
{{#each bp-whos-who.people}}
doc
●●●
{{{title}}}
{{{name}}} {{{addComma prof}}}
{{{desc}}}
{{#if disclosureTitle }} Disclosure
Disclosure
{{{disclosureTitle}}}
{{{disclosureText}}}
{{/if}}
More on Non-Hodgkin Lymphoma